Viridian Therapeutics, Inc.\DE (VRDN)
↓ Download CSV- Sector Manufacturing
- Incorporated DE
- Fiscal year ends Dec 31
In fiscal 2025, Viridian Therapeutics, Inc.\DE reported revenue of $70.85M, up 23359.9% from the prior year. The company ran a net loss, with a net margin of -483.6%. It held $899.42M in total assets against $177.25M in total liabilities.
Key ratios (FY2025)
-512.9%
Operating margin
-483.6%
Net margin
-47.4%
Return on equity
+23359.9%
Revenue growth (YoY)
| Metric (FY) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $70.85M | $302.0K | $314.0K | $1.77M | $2.96M | $1.05M | $4.46M | $8.39M | $4.00M | — |
| Cost of Revenue | — | — | — | — | — | — | — | — | — | $2.55M |
| Operating Income | -$363.39M | -$299.04M | -$254.45M | -$134.30M | -$79.73M | -$110.38M | -$41.98M | -$33.08M | -$26.53M | -$16.99M |
| Net Income | -$342.60M | -$269.95M | -$237.73M | -$129.87M | -$79.41M | -$110.72M | -$41.87M | -$32.70M | -$26.51M | -$17.27M |
| EPS (Diluted) | — | — | $-5.31 | $-4.05 | $-6.66 | $-31.13 | — | — | — | — |
| Total Assets | $899.42M | $742.40M | $490.42M | $435.09M | $203.71M | $131.25M | $30.26M | $66.15M | $52.48M | $24.76M |
| Total Liabilities | $177.25M | $70.76M | $48.40M | $40.03M | $15.99M | $11.22M | $14.51M | $14.80M | $13.97M | $9.71M |
| Shareholders' Equity | $722.17M | $671.64M | $442.02M | $395.06M | $187.72M | $120.04M | $15.75M | $51.34M | $38.51M | -$61.92M |
| Cash & Equivalents | — | — | — | — | — | — | — | $32.61M | $47.44M | $22.10M |
| Operating Cash Flow | -$276.39M | -$232.32M | -$184.17M | -$93.84M | -$54.58M | -$29.78M | -$36.06M | -$26.84M | -$28.17M | -$14.76M |
| Capital Expenditures | $495.0K | $511.0K | $898.0K | $797.0K | $338.0K | $42.0K | $84.0K | $445.0K | $246.0K | $250.0K |
| Shares Outstanding | 101.83M | 80.99M | 53.99M | 41.31M | 23.92M | 4.23M | 2.32M | 30.84M | 22.57M | 833.7K |